Compare 10X Genomics Inc (TXG) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Block Inc — how do they compare? 10X Genomics Inc trades at $80.65 (market cap $10.07B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Block Inc is far larger — about 4.5× 10X Genomics Inc's market cap, and Block Inc is more actively traded (8,386,094 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Block Inc for 78 Days on average.
| TXG | XYZ | |
|---|---|---|
Market Cap | $10.07B | $45.20B |
Volume | 5,657,286 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $97.74 | $84.85 |
52-Week Low | $11.48 | $49.04 |
Typical Hold Time | 91 Days | 78 Days |
Enterprise Value | $9.59B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
XYZ trades at $75.21, down 1.13% on the day, with a bearish technical signal but strong analyst support. The company reported mixed earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 results pending. Revenue growth has been steady, reaching $24.19B in 2025, though net income margin compressed to 1.43%. Cash flow trends show volatility, with 2025 net cash flow negative $749.24M due to heavy investing activity.
The stock offers potential upside to the consensus price target of $97.47, supported by a 76.9% buy rating from analysts. However, risks include high P/E of 134.34, margin pressures, and insider selling. Positive developments include expanding partnerships and a potential federal trust bank application, which could enhance profitability long-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
